Evotec’s Strategic Pivot: A Milestone Amid Restructuring

The German biotechnology firm Evotec SE finds itself at a critical juncture, marked by a significant clinical milestone that starkly contrasts with its ongoing corporate overhaul. On Thursday, the company announced progress in its oncology collaboration with Bristol Myers Squibb (BMS), triggering a $10 million milestone payment. This development involves the initiation of a Phase 1 clinical trial for the drug candidate BMS-986506, targeting clear cell renal cell carcinoma.

This trial represents a key advancement for the partners’ targeted protein degradation alliance, established in 2018, marking its first entry into the clinical stage. Evotec’s contribution leverages its artificial intelligence-driven data analytics platform to identify molecular glues. This innovative approach aims to induce cancer cells to degrade disease-causing proteins autonomously.

Financial Headwinds and a Restructured Horizon

The scientific achievement arrives against a backdrop of considerable financial strain. The company’s recent “Horizon” restructuring initiative outlines a plan to consolidate its global operational footprint from 19 sites to just 10 over the next two years. This consolidation is expected to impact up to 800 positions.

Should investors sell immediately? Or is it worth buying Evotec?

Furthermore, Evotec’s financial guidance for 2026 disappointed market observers. The company’s projected adjusted EBITDA, forecasted between €0 and €40 million, falls substantially short of previous analyst consensus estimates of approximately €81 million. This fundamental weakness is reflected in the equity’s performance. The shares currently trade around €4.28, hovering just above their 52-week low of €4.14, and have declined more than 30% over the past 30 trading days.

Biologics Division Emerges as Growth Engine

A review of preliminary 2025 results reveals a notable shift in the company’s internal profit drivers. Evotec’s traditional preclinical development segment contracted by 13% and slipped into an operational loss. In sharp contrast, the Just Evotec Biologics division expanded by roughly 40%. This unit is anticipated to contribute approximately €53 million to the adjusted operating profit, providing crucial support for the medium-term objective of achieving a 20% EBITDA margin by 2028.

Investors await further details when management presents the final audited financial statements for the 2025 fiscal year on April 8. This presentation is expected to provide a clearer timeline for the anticipated cost savings from the newly launched restructuring program.